TAK 931

Drug Profile

TAK 931

Latest Information Update: 20 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Takeda Oncology
  • Class Antineoplastics; Small molecules
  • Mechanism of Action CDC7 protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Colorectal cancer; Pancreatic cancer
  • Phase I Solid tumours

Most Recent Events

  • 01 Jun 2018 Safety, efficacy, pharmacokinetics and pharmacodynamics data from phase I trial in Solid tumors presented at 54th Annual Meeting of the American Society of Clinical Oncology (ASCO-2018)
  • 25 Oct 2017 Phase-II clinical trials in Colorectal cancer (Metastatic disease, Second-line therapy or greater) in USA (PO) (NCT03261947)
  • 25 Oct 2017 Phase-II clinical trials in Pancreatic cancer (Metastatic disease, Second-line therapy or greater) in USA (PO) (NCT03261947)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top